Panel submits operational evaluation of FDA’s tobacco program

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero
“We seem to have a risk of exposure that needed that extra boost of the cigarette to cause the cancer.”

Twenty-five years ago, the attack on the World Trade Center engulfed Ground Zero in a shroud of smoke, leaving Lower Manhattan covered in toxic dust for months.

Heidi Overton selected as FDA commissioner; Jared Seehafer named inaugural Deputy Commissioner for Technology and AI

As part of a sweep of leadership changes at FDA, Heidi Overton, deputy director of the White House Domestic Policy Council, has been nominated to the role of FDA commissioner.

September 11, 2026

Vol.52 No.33

By Claire Marie Porter

Cancer Policy

FDA authorizes second e-cigarette with age-gating features

FDA cleared the JUUL2 e-cigarette in tobacco and menthol flavors. This is the second vaping device the agency has authorized that incorporates age-gating technology—features intended to block access to minors and to keep e-cigarettes out of the hands of never-smokers at a vulnerable age.

FDA grants accelerated approval to iberdomide combination for MM

FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

September 11, 2026

Vol.52 No.33

Drugs & Targets

FDA grants accelerated approval to camizestrant combination for HR+ metastatic breast cancer

FDA granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on an FDA-authorized test.

September 11, 2026

Vol.52 No.33

Drugs & Targets

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC

FDA granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

September 11, 2026

Vol.52 No.33

Panel submits operational evaluation of FDA’s tobacco program

YOU MAY BE INTERESTED IN

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero
“We seem to have a risk of exposure that needed that extra boost of the cigarette to cause the cancer.”

Heidi Overton selected as FDA commissioner; Jared Seehafer named inaugural Deputy Commissioner for Technology and AI

FDA authorizes second e-cigarette with age-gating features

FDA grants accelerated approval to iberdomide combination for MM

FDA grants accelerated approval to camizestrant combination for HR+ metastatic breast cancer

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login

Panel submits operational evaluation of FDA’s tobacco program

YOU MAY BE INTERESTED IN

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero“We seem to have a risk of exposure that needed that extra boost of the cigarette to cause the cancer.”

Heidi Overton selected as FDA commissioner; Jared Seehafer named inaugural Deputy Commissioner for Technology and AI

FDA authorizes second e-cigarette with age-gating features

FDA grants accelerated approval to iberdomide combination for MM

FDA grants accelerated approval to camizestrant combination for HR+ metastatic breast cancer

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC

Never miss an issue!

Login

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero
“We seem to have a risk of exposure that needed that extra boost of the cigarette to cause the cancer.”